Biomeme
Eli Lilly

Zepbound

Tirzepatide

Tirzepatide branded for weight management — same molecule as Mounjaro.

Chronic Weight Management 22.5% avg weight loss
81 B+

Response Score

ⓘ For informational purposes only — not medical advice.

Score Breakdown

mRNA Monitoring Compatibility 18/20
Weight Loss Efficacy 20/20
Tolerability 15/20
Cardiovascular Evidence 14/20
Muscle Preservation 14/20

Overview

Zepbound is tirzepatide branded specifically for chronic weight management by Eli Lilly. It is the same molecule as Mounjaro but approved under a distinct indication for adults with a BMI ≥30, or ≥27 with at least one weight-related comorbidity. The SURMOUNT trial program demonstrated industry-leading weight loss results.

Mechanism of Action

Identical to Mounjaro — tirzepatide is a dual GIP/GLP-1 receptor agonist. The dual mechanism enhances insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through central and peripheral pathways.

Clinical Evidence

SURMOUNT-1 showed 22.5% mean weight loss at 15 mg over 72 weeks. SURMOUNT-3 demonstrated that tirzepatide maintained weight loss achieved during a 12-week intensive lifestyle intervention. SURMOUNT-4 showed that continued tirzepatide treatment prevented weight regain compared to switching to placebo.

mRNA Monitoring Insight

Transcriptomic monitoring of Zepbound patients provides the same dual-pathway visibility as Mounjaro. Key gene expression markers span inflammatory cytokines, adipokines, and metabolic regulators. Biomeme's platform enables longitudinal tracking of these markers to assess whether the molecular response is sustained over time — critical for weight management where treatment duration is indefinite.

Side Effects & Safety

GI side effects (nausea, diarrhea, vomiting, constipation) are the most common, consistent with Mounjaro. The dose-titration schedule is designed to mitigate initial GI intolerance. Thyroid C-cell tumor warnings apply as with all GLP-1 class medications.

FAQ

What is the difference between Zepbound and Mounjaro?
They are the same molecule (tirzepatide) made by the same manufacturer (Eli Lilly). Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Dosing and the molecule itself are identical.

Quick Facts

Generic
Tirzepatide
Manufacturer
Eli Lilly
Key Trial
SURMOUNT-1
Score
81/100 (B+)

Sources

  1. [1] Zepbound FDA Approval — Eli Lilly

Compare Others

Track Your Zepbound Response.

Biomeme's GLP-1 Response Panel monitors molecular changes so you know your medication is working — weeks before the scale moves.

Contact Us